Why the study?
SARS-CoV-2 entry via angiotensin-converting enzyme 2 and the high prevalence of hypertension in COVID-19 prompted questions regarding patient management, particularly renin-angiotensin-aldosterone system inhibitor use.
This expert consensus from the Russian Medical Society for Arterial Hypertension provides guidance on the management of hypertension and the use of RAAS inhibitors in patients with COVID-19.
The novel coronavirus infection (COVID-19) caused by the b-coronavirus SARS-CoV-2, and leads to acute respiratory distress-syndrome, has affected more than nineteen million people worldwide, resulting in 0.7 million deaths as of August 2020. The fact that the virus uses angiotensin-converting enzyme 2 as a receptor for entering the target cell, and the high prevalence of hypertension and other cardiovascular diseases among patients with COVID-19, have caused serious discussions on the management of such patients. This consensus of experts from the Russian Medical Society for Arterial Hypertension analyzed the existing data on the relationship between COVID-19 and hypertension, the pathophysiological aspects of the penetration of the virus into target cells and the use of renin-angiotensin-aldosterone system inhibitors in patients with hypertension and COVID-19.
No takes yet. Share an insight, caveat, or question.
Чазова et al. (2020) conducted a review in Hypertension and COVID-19. Renin-angiotensin-aldosterone system inhibitors was evaluated. This expert consensus analyzed existing data on the relationship between COVID-19 and hypertension, viral penetration mechanisms, and the use of renin-angiotensin-aldosterone system inhibitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: